Stockreport

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Intelligent Bio Solutions Inc.  (INBS) 
PDF Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission wit [Read more]